| DIRECT COMPETITOR COMPARISON | |
| AFFY | AMGN | Pvt1 | RHHBY.PK | Industry | | Market Cap: | 406.53M | 57.77B | N/A | N/A | 94.68M | | Employees: | 147 | 16,700 | N/A | N/A | 65 | | Qtrly Rev Growth (yoy): | 34.70% | -1.60% | N/A | N/A | 19.70% | | Revenue (ttm): | 107.29M | 14.58B | N/A | N/A | 14.05M | | Gross Margin (ttm): | -46.57% | 84.99% | N/A | N/A | 64.07% | | EBITDA (ttm): | -87.84M | 6.71B | N/A | N/A | -12.30M | | Oper Margins (ttm): | -83.68% | 38.71% | N/A | N/A | -124.89% | | Net Income (ttm): | -88.02M | 4.74B | N/A | N/A | N/A | | EPS (ttm): | -5.054 | 4.585 | N/A | N/A | -0.32 | | P/E (ttm): | N/A | 12.45 | N/A | N/A | 17.01 | | PEG (5 yr expected): | N/A | 1.32 | N/A | 1.37 | 1.31 | | P/S (ttm): | 3.76 | 3.94 | N/A | N/A | 9.57 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.53 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | AMGN | | Dream Stocks for Biotech Investors
Wed 3:27pm -
at Motley Fool | | • | AMGN | | Novartis Didn't Know JAK, Until Now
Wed 2:41pm -
at Motley Fool | | • | RHHBY.PK | | Inhibition of Cell Migration by Gene Silencing - Measured with the xCELLigence Cell Analysis System from Roche
Wed 8:00am -
Business Wire | | • | AMGN | | Beacon Equity Issues Technical Trading Overview for NexMed Inc.
Wed 6:50am -
GlobeNewswire | | • | AMGN | | [video] Topping the Tape
Tue, Nov 24 -
at CNBC | | • | AMGN | | Signals Favor a Santa Claus Rally
Tue, Nov 24 -
at Minyanville.com | | • | RHHBY.PK | | Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Mon, Nov 23 -
PR Newswire | | • | RHHBY.PK | | Spectrum Pharma: Zevalin Sales Ramp Up
Sun, Nov 22 -
at Seeking Alpha | | • | RHHBY.PK | | Desktop Bug Detector
Fri, Nov 20 -
at Forbes.com | | • | RHHBY.PK | | Biotech Stocks: Senate bill weighs on Allergan, Medicis
Thu, Nov 19 -
at MarketWatch | | • | RHHBY.PK | | 454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System Including 1,000 bp Reads for 2010
Thu, Nov 19 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
Competitors
